Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €435.59 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 10:30 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008

France

Phone: 33 1 53 77 40 00

Fax: 33 1 53 77 42 96

Sanofi engages in the research, development, manufacture, and marketing of healthcare products worldwide. Principal Activities The company is organized around three principal activities: Pharmaceuticals, Human Vaccines through Sanofi Pasteur, and Animal Health through Merial. The company invests in various activities, such as Emerging Markets; and Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. Pharmaceutical Products Within the Pharmaceuticals business, the company’s major products could be grouped into the major fields of diabetes solutions, rare diseases, multiple sclerosis (MS), oncology, thrombosis and cardiovascular disease prevention, nephrology, and biosurgery. The company has also developed a presence in CHC and generics. Diabetes Solutions Afrezza: Afrezza is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes. The product was launched in the United States at the beginning of February 2015. Afrezza is in-licensed from MannKind Corporation. Toujeo (Insulin glargine 300 U/mL): In Phase I studies, Toujeo, a new formulation of insulin glargine, demonstrated improved pharmacodynamics with an even flatter and more prolonged action profile than Lantus, which in clinical trials translated into good glycemic outcomes with less hypoglycemia. In February 2015, the U.S. Food and Drug Administration (FDA) approved Toujeo (insulin glargine (rDNA origin) injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of the second quarter of 2015. Toujeo would be available in the Toujeo SoloSTAR, a disposable prefilled pen, which contains 450 units of Toujeo and requires one third of the injection volume to deliver the same number of insulin units as compared to the Lantus SoloSTAR. Toujeo is pending marketing authorization with other health authorities around the world. Lantus: Lantus (insulin glargine) is a long acting analog of human insulin, offering an improved pharmacokinetic and pharmacodynamic profile. Lantus is indicated for once daily subcutaneous administration in the treatment of adult patients with type 2 diabetes mellitus who require basal insulin for the control of hyperglycemia, and for adult and pediatric patients (label extension for pediatric use was granted in the E.U. in 2012) aged two years with type 1 diabetes mellitus. Lantus could be administered subcutaneously using syringes or specific pens, including Lantus SoloSTAR, a pre filled disposable pen available in approximately 120 countries worldwide, and the only disposable pen that combines a low injection force of approximately 80 units per injection with ease of use; ClikSTAR, a reusable insulin pen first approved in the European Union and Canada and available in approximately 30 countries worldwide; and AllSTAR, the first reusable insulin pen developed primarily for people with diabetes in emerging markets, indicated for use with the company’s insulin portfolio. AllSTAR is available in India, going forward, the company intends to make AllSTAR accessible to other emerging markets. Lantus is available in approximately 120 countries worldwide. The primary countries for sales of Lantus in 2014 were the United States, France, China, and Germany. The company also has patents protecting the Lantus formulation and devices, which deliver Lantus that are in litigation and which expire on varying dates between 2023 and 2028 (including pediatric regulatory exclusivity). Amaryl/Amarel/Solosa: Amaryl (glimepiride) is an orally administered once daily sulfonylurea (a glucose lowering agent), available either in simple form or in combination with metformin, indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. Amaryl reduces the body's blood sugar level in two ways, such as by helping the body to produce more insulin both at mealtimes and between meals, and by decreasing insulin resistance. Amaryl is subject to generic competition i

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHPP:FP €435.59 EUR 0.00

RHPP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.21 USD -0.30
Amgen Inc $153.26 USD -1.73
Bayer AG €126.31 EUR -0.59
Bristol-Myers Squibb Co $67.48 USD -0.19
Novo Nordisk A/S kr368.70 DKK -2.20
View Industry Companies
 

Industry Analysis

RHPP

Industry Average

Valuation RHPP Industry Range
Price/Earnings 27.9x
Price/Sales 3.4x
Price/Book 2.1x
Price/Cash Flow 17.7x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-TITR PART10%87, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.